Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

David Ajayi, a Nigerian-born data science leader, is redefining clinical research infrastructure and digital health systems ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly and Johnson & Johnson, PPH’s largest holdings, are facing unique challenges, impacting the ETF’s overall ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

The incidence of obesity and diabetes is rising in India, the world’s most populous country, which also ranks among the worst ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...